title: Thrombotic thrombocytopenic purpura during interferon alpha treatment for chronic myelogenous leukemia.
abstract: Thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome have recently been observed in patients undergoing interferon alpha (IFN-alpha) therapy. However, the relationship between disease and therapy has not been established, essentially because of concomitant treatment or previous bone marrow transplantation. We present a case of TTP developing during IFN-alpha therapy for chronic myelogenous leukemia. In this case, IFN-alpha seems to be the only etiological agent.
authors.affiliation: Department of Hematology and Clinical Oncology, CHU La Miletrie, Poitiers, France.
authors.forename: L
authors.initials: L
authors.lastname: Lacotte
authors.forename: A
authors.initials: A
authors.lastname: Thierry
authors.forename: V
authors.initials: V
authors.lastname: Delwail
authors.forename: B
authors.initials: B
authors.lastname: Dreyfus
authors.forename: F
authors.initials: F
authors.lastname: Guilhot
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000150:complications / Q000188:drug therapy*; D008297:Male; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced* / Q000150:complications
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha